Jupiter Wellness, Inc.: Jupiter Wellness Announces First Pat

Jupiter Wellness, Inc.: Jupiter Wellness Announces First Patient Dosing for Double-Blinded Placebo Controlled Trial of JW-300 for the Treatment of First Degree Burns

JUPITER, FL / ACCESSWIRE / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced

Related Keywords

United States , Kostenloser Wertpapierhandel , Brian John , Jupiter Wellness Inc , Nasdaq , Jupiter Wellness , Private Securities Litigation Reform Act , Jupiter , Wellness , Nnounces , First , Patient , Closing , Double , Blinded , Placebo , Ontrolled , Trial , Treatment , Degree , Turns ,